Compare Incyte Corporation (INCY) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Noble Corporation plc — how do they compare? Incyte Corporation trades at $120.67 (market cap $24.54B), while Noble Corporation plc trades at $44.09 (market cap $7.10B). The key difference: Incyte Corporation is far larger — about 3.5× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.5% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | NE | |
|---|---|---|
Market Cap | $24.54B | $7.10B |
Sector | Health | Technology |
52-Week High | $129.93 | $54.37 |
52-Week Low | $81.61 | $26.61 |
Enterprise Value | $20.04B | $8.53B |
Dividend Yield | — | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Noble Corporation (NE) trades at $44.21, up 1.52% today, with a mixed technical and fundamental backdrop. The stock exhibits a bullish trend in moving averages but faces resistance near $45-$46. Recent Q2 2026 earnings of $0.01 per share missed expectations, though the company secured $200 million in new contracts and maintains a $6.8 billion backlog. Positive cash flow from operations of $952 million in 2025 supports financial stability, but net income declined year-over-year.
The outlook is cautiously optimistic, with a consensus price target of $46 offering modest upside. Key opportunities include strong contract backlog and operational cash flow, while risks involve earnings volatility, ongoing legal investigations, and competitive pressures in offshore drilling. Analyst sentiment is divided, with 31% buy ratings reflecting balanced optimism and caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
